Latest Conference Articles

Community oncology faces high costs and staffing hurdles for trials; Lucio N. Gordan, MD, urges pragmatic designs matching real-world patients.

In part 2, David Johnson, MD, MPH, discusses how real-time data can sustain gold carding, ease prior authorization burden, and ensure accountability.

Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.

Adaolisa Anaka, PharmD, BCACP, AAHIVP, discusses a pharmacist-led model that targets access barriers to GLP-1 obesity therapy.

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

Liquid biopsy and at-home phlebotomy are closing precision medicine access gaps nationwide, though tissue remains the gold standard.

At NASP's inSPire2026, covered entities and manufacturers debate 340B program reform, contract pharmacies, and the 2027 rebate model.

Irfana Lakada, PharmD, CSP, explains why onboarding may be the wrong time to screen for social needs and why rescreening matters.

Jesse Dresser explains how federal PBM reform, a new CMS RFI, and FTC settlements could reshape specialty pharmacy contracts and pay from 2027.

Karen van Caulil, PhD, explained why employers evaluating cancer care weigh timely access, quality, and equity alongside cost.

Stephen "Fred" Divers, MD, discusses how COA study data push back on payer bias and support community oncology's long-term sustainability.

Physicians to Discuss 2026 Oncology Care Index at Patient-Centered Oncology Care®, Premier Annual AJMC® Event Starting Today in Nashville | 60% of Community Physicians Say Clinical Trial Options Are Limited; 93% Say Pragmatic Designs Would Help

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

David Johnson, MD, MPH, discusses how payer data can reduce low-value cancer care and steer patients to supportive services and cost-efficient sites.

Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.

Stephen “Fred” Divers, MD, discusses findings showing community oncology delivers outcomes comparable with academic care for breast cancer and NSCLC.

Stephen "Fred" Divers, MD, previews PCOC 2026, including his session on the Oncology Care Index and the gap in AI adoption in oncology.

Christine Pfaff, RPh, MBA, discusses barriers to community cellular therapy delivery and the need for new business models and payer collaboration.

Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.

Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.

J&J's Oncology Care Index finds a systems problem, not a confidence gap, in community oncology, Mahadi Baig, MD, says.

Bundled payment models offer employers and community oncology practices greater cost predictability while improving patient access, Baird said.

Jeff Hunnicutt emphasized vetting prior authorization vendors, scaling beyond single use cases, and AI's potential to streamline workflows.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Rosa Novo discusses tailoring cancer benefits to workforce needs, improving access and prevention, and return-to-work support.

Employers can advance patient-centered oncology care through proactive benefits, quality data, navigation, and tailored support, Amanda Green, MPH, said.